Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ezetimibe

- PMLiVE

PD1 drugs could end ‘decades of silence’ in bladder cancer therapy

Merck's Keytruda and Roche antibody showing promise

- PMLiVE

Merck & Co plays catch-up with osteoporosis data for odanacatib

Says study shows significant reduced risk of osteoporotic symptoms

- PMLiVE

Merck forges on with Vytorin trial after safety review

Won't halt controversial study of its cholesterol drug

- PMLiVE

Merck settles Vytorin lawsuit for $688m

Had faced claims it held back negative data from clinical trials

- PMLiVE

Merck blocks Mylan’s generic Zetia and Vytorin after appeal

Keeps patents of cholesterol medicines protected until April 2017

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links